Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NatHaLi-01: UCART20x22 in Relapsed/Refractory B-NHL
NCT05607420Phase 2Recruiting
- Sponsor
- Cellectis
- Start
- Nov 2022
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of UCART20x22 in B-cell non-Hodgkin lymphoma, sponsored by Cellectis. Started Nov 2022; status: recruiting.
02
Drugs
UCART20x22
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05607420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607420.